Organization
The CGC Management Team is responsible for strategic decisions and execution of the CGC program. The scientific director acts as chairman of the management team. The management team will seek advice and comments from the CGC scientific committee, which consists of all participants of the CGC. This committee discusses scientific progress and future plans of the Centre and advises the management on strategic matters. The scientific director acts as chairman of the scientific committee.
The management team consists of:
Hans Bos, scientific director
Annelies Speksnijder, managing director
Koen Verhoef, valorisation manager
Anton Berns, representative NKI
Frank Grosveld, representative Erasmus MC
Hans Clevers, representative Hubrecht
The CGC has installed a Valorisation Board that serves as an advisory board to the management team and is available for consultancy for the CGC PI’s. This board operates on a consultancy base. Its members are:
Dr. Ton Logtenberg, founder and former CEO of Crucell, currently CEO of Merus and Agamyxis
Dr. Johan Renes, registered European patent attorney and partner in the Intellectual Property Expert Group (IPEG)
Mr. Pieter van der Meer. Senior partner in Gilde Investment and board member of Agendia, one of the most successful spin-offs of GCG
Dr. Gerard van Odijk, former Senior Vice President and Area Director of GlaxoSmithKline Northern Europe, since 2006 president and CEO of Teva Pharmaceutical Europe B.V.